Navigation Links
FLIPR Calcium 3 Assay Kit Datasheet

SUPERIOR DETECTION FOR DIVERSIFIED TARGETS



NO WASH STEPS

ADHERENT AND NONADHERENT CELL TYPES

HIGHER SIGNAL INTENSITY

IMPROVED DATA QUALITY

COMPATIBLE WITH MORE TARGETS


FLIPR ASSAYS FOR GPCRS
Calcium mobilization assays for screening GPCR targets are preferred techniques in drug discovery because they generate high quality leads. Molecular Devices FLIPR system is the method of choice among pharmaceutical and biotechnology companies for screening calcium flux assays in high throughput. Molecular Devices FlexStationis also commonly used in assay development, target validation and lower throughput applications.


OPTIMIZED ASSAYS
To simplify assay development and optimize performance on both FLIPR and FlexStation, Molecular Devices has developed a series of no-wash assay kits. The combination of proprietary chemistry and a no-wash protocol causes less cellular disruption than traditional methods to generate consistent results and strong signals. FLIPR Assay Kits provide the easiest way to get the best performance from your FLIPR or FlexStation system.


PATENTED TECHNOLOGY
FLIPR Assay Kits from Molecular Devices employ a quenching dye to reduce background fluorescence and improve the signal-to-noise ratio. The patented quench technology (U.S. patent number 6,420,183, EPO patent number 0 906 572) is offered to drug discovery and life science researchers exclusively by Molecular Devices, through purchase of FLIPR Assay Kits.


UNIVERSAL FORMAT
Using the patented quench technology and advances in reagent chemistry, the FLIPR Calcium 3 Assay Kit provides an improvement in signal strength and data quality over previous methods. The assay protocol results in fewer spontaneous calcium fluxes and unresponsive cells.

When compared with the standard FLUO-3AM dye incubation-and-wash procedure, assay signal intensity using the FLIPR Calcium 3 Assay Kit is substantially higher and more distinct, resulting in superior detection. Compared to the standard FLUO-4 AM dye incubation-and-wash procedure, the kit produces equivalent or greater signal intensity (See Figure 1) and better well-to-well uniformity resulting in superior data quality and a higher Z-factor. This allows the researcher to accurately and easily detect intracellular calcium fluxes even from chemokine and small peptide targets, as well as transient, endogenous and low-expression receptors that have been difficult to assay with standard methods. Strong signals are attained in cases that may previously have yielded weak signal intensity or no peak at all. Thus, the FLIPR Calcium 3 Assay Kit negates the need for having multiple calcium flux assay chemistries for different receptor targets.


RAPID ASSAY DEVELOPMENT
The streamlined, homogeneous format makes the FLIPR Calcium 3 Assay Kit less labor intensive to run. With the Mix-and-Read procedure, the cells can be incubated with the reagents and are stable for up to several hours. Rapid analysis of the cells can be followed with detection on a FLIPR system or FlexStation microplate reader.


INCREASED THROUGHPUT

The FLIPR Calcium 3 Assay Kit increases throughput by eliminating cumbersome wash steps. Less preparation time is required for wash buffers and wash calibrations. This successfully eliminates causes for variability in the data, resulting in fewer false positives and negatives. The kit is designed to work at room temperature, which is conducive to automation using stackers or robots. Larger unit volume packaging in the Express Kit format minimizes reagent bottle an d liquid handling.


REDUCED ASSAY FAILURES
Cell detachment, lowered cell competency and incomplete dye washing are common problems that are easily avoided by using the FLIPR Calcium 3 Assay Kit. In addition, the elimination of potential dispensing and washing errors, or associated equipment failures, further insures the integrity of screening operations.


ORDERING INFORMATION
FLIPR Calcium 3 Assay Explorer Kit: Part Number: R8091
(10) 1 ml reagent vials
(1) buffer bottle
Provides sufficient reagent for 10 plates (96- or 384-well)

FLIPR Calcium 3 Assay Bulk Kit: Part Number: R8090
(10) 10 ml reagent vials
Provides sufficient reagent for 100 plates (96- or 384-well)

FLIPR Calcium 3 Assay Express Kit: Part Number: R8108
(2) 50 ml reagent vials
Provides sufficient reagent for 100 plates (96- or 384-well)


SALES OFFICES
USA 800-635-5577
UK +44-118-944-8000
Germany +49-89-9620-2340
Japan +06-6399-8211

Check our web site for a current listing of our worldwide distributors.
www.moleculardevices.com


FLIPR is a registered trademark and FLEXstation is a trademark of Molecular Devices Corporation.


back to top


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. FLIPR Calcium Assay Kit Datasheet
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. Gq-coupled receptor assays: a comparison of FLEXstation and FLIPR
4. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
5. Cis-Reporting System Monitors Intracellular Calcium Mobilization
6. Cis-Reporting System Monitors Intracellular Calcium Mobilization
7. Calcium Plus Assay Kit, Superior Detection for Specialized Targets
8. Calcium Flux Assays using the LabChip 3000
9. HEK293 Calcium Flux Assay
10. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
11. Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" )
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... Feb. 3, 2016 New Jersey Health Foundation ... $1 million for researchers in New ... research that demonstrates exciting potential.   ... for the New Jersey Health Foundation Research Grant ... these educational institutions— Princeton University, Rutgers University, Rowan ...
(Date:2/3/2016)... , Feb. 3, 2016  Silk Therapeutics, Inc., today ... round. Silk Therapeutics has now raised a total of $10.25 ... by the company. The Series A2 round was led by ... , with participation from new investors Lear Corporation and ... and Roy P. Disney ; Richard Sackler , MD, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):